203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

Somatic mutation discovery in idiopathic multicentric castleman disease iMCD lymph node tissue identifies dysregulated intracellular calcium signaling as a potential disease mechanism and therapeutic target

Siltuximab mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease

An open label Phase II trial of VDJ 001 a high affinity IL 6R antagonist antibody for the treatment of patients with idiopathic multicentric castleman disease

Increased type I interferon signaling is a hallmark of idiopathic multicentric castleman disease

Aiming at immune fitness in cancer Longitudinal functional profiling to predict clinical outcome

PRKRA associated with NF κB activation in pulmonary involvement of idiopathic multicentric castleman disease

RPS6 acts as a translational checkpoint to limit effector skewing and sustain CD8 T cell memory

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease tafro and NOS subtypes

Impaired coordination between innate and adaptive immunity in hematologic and solid cancer patients following sars cov 2 infection or vaccination

Immunological and transcriptomic analysis of febrile neutropenia in hematological malignancies SOCS3 IL 6 NETs axis and NOD like receptor signaling dysregulation